Elizabeth Challenger

Liverpool, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study.

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study.

Journal: Clinical pharmacology and therapeutics

Published: October 08, 2025

The tear production of tecovirimat in a single hospitalized mpox patient: a pharmacokinetic analysis.

The tear production of tecovirimat in a single hospitalized mpox patient: a pharmacokinetic analysis.

Journal: The Journal of antimicrobial chemotherapy

Published: March 20, 2025

A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5'-triphosphate (T-705-RTP) in human peripheral mononuclear cells.

A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5'-triphosphate (T-705-RTP) in human peripheral mononuclear cells.

Journal: Journal of pharmaceutical and biomedical analysis

Published: February 02, 2024

Clinical, pharmacological, and qualitative characterization of drug-drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa.

Clinical, pharmacological, and qualitative characterization of drug-drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa.

Journal: The Journal of antimicrobial chemotherapy

Published: December 01, 2023

Development and validation of an LC-MS/MS method for quantification of favipiravir in human plasma.

Development and validation of an LC-MS/MS method for quantification of favipiravir in human plasma.

Journal: Journal of pharmaceutical and biomedical analysis

Published: March 24, 2023

Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP).

Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP).

Journal: The Journal of antimicrobial chemotherapy

Published: January 17, 2021

The development and validation of a novel LC-MS/MS method for the quantification of cenicriviroc in human plasma and cerebrospinal fluid.

The development and validation of a novel LC-MS/MS method for the quantification of cenicriviroc in human plasma and cerebrospinal fluid.

Journal: Biomedical chromatography : BMC

Published: April 12, 2019

Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.

Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.

Journal: The Journal of antimicrobial chemotherapy

Published: February 20, 2019

Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milk.

Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milk.

Journal: Bioanalysis

Published: November 20, 2018

Cerebrospinal fluid exposure of cenicriviroc in HIV-positive individuals with cognitive impairment.

Cerebrospinal fluid exposure of cenicriviroc in HIV-positive individuals with cognitive impairment.

Journal: British journal of clinical pharmacology

Published: October 08, 2018

Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.

Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.

Journal: The Journal of antimicrobial chemotherapy

Published: May 25, 2018

Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.

Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.

Journal: The Journal of antimicrobial chemotherapy

Published: August 03, 2017

Showing 1-12 of 13

Last Updated: 09/26/2026